Agenus Inc
Company Profile
Business description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Contact
3 Forbes Road
LexingtonMA02421
USAT: +1 781 674-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
316
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,467.00 | 4.40 | 0.05% |
| CAC 40 | 7,840.11 | 96.36 | 1.24% |
| DAX 40 | 23,577.88 | 78.56 | 0.33% |
| Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
| FTSE 100 | 8,587.16 | 32.36 | 0.38% |
| HKSE | 23,549.46 | 681.72 | 2.98% |
| NASDAQ | 17,928.92 | 0.78 | 0.00% |
| Nikkei 225 | 37,644.26 | 140.93 | 0.38% |
| NZX 50 Index | 12,676.75 | 71.68 | 0.57% |
| S&P 500 | 5,659.91 | 4.03 | -0.07% |
| S&P/ASX 200 | 8,233.50 | 2.30 | 0.03% |
| SSE Composite Index | 3,369.24 | 27.25 | 0.82% |